A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 990 shares of NRIX stock, worth $19,780. This represents 0.0% of its overall portfolio holdings.

Number of Shares
990
Previous 1,690 41.42%
Holding current value
$19,780
Previous $35,000 37.14%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$18.93 - $25.69 $13,251 - $17,983
-700 Reduced 41.42%
990 $22,000
Q2 2024

Aug 14, 2024

BUY
$12.02 - $21.3 $5,889 - $10,437
490 Added 40.83%
1,690 $35,000
Q1 2024

May 15, 2024

BUY
$7.77 - $15.66 $9,324 - $18,792
1,200 New
1,200 $17.6 Million
Q2 2023

Aug 14, 2024

BUY
$8.7 - $13.28 $6,089 - $9,296
700 Added 140.0%
1,200 $12 Million
Q1 2023

Aug 14, 2024

SELL
$8.56 - $13.26 $10,186 - $15,779
-1,190 Reduced 70.41%
500 $4.44 Million

Others Institutions Holding NRIX

About Nurix Therapeutics, Inc.


  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $942M
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Federation Des Caisses Desjardins Du Quebec Portfolio

Follow Federation Des Caisses Desjardins Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.